# AMS VS MOXI Ketek vs Avelox in AMS

> **NCT00537563** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 351 (actual)

## Conditions studied

- Maxillary Sinusitis

## Interventions

- **DRUG:** Telithromycin

## Key facts

- **NCT ID:** NCT00537563
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2012-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537563, "AMS VS MOXI Ketek vs Avelox in AMS". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00537563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*